[Prevention of gastroduodenal lesions induced by non-steroidal anti-inflammatory agents. Economic analysis from a survey of 356 physicians].
In order to obtain information on prescribing habits concerning the prevention of gastroduodenal lesions induced by non-steroidal anti-inflammatory agents (NSAI), 356 physicians practicing in 2 French departments were asked to fill a posted questionnaire. Fifty-one percent of these doctors gave an assessable answer. Among these, 84 percent occasionally prescribe "gastric protectors" associated with NSAI's in 32 percent of the prescriptions. They use antacids (48 percent), anti-H2 products (27 percent), sucralfate (11 percent) or prostaglandins (13 percent). This represents a daily cost of additional treatment ranging from 0.87 to 2.49 francs. If fibroscopies and further consultations necessitated by the prescription of NSAI's are taken into account, then 86 to 140 percent must be added to the cost of NSAI's. The profitability of these preventive measures in terms of public health will be really estimated only when the number of severe gastroduodenal lesions effectively prevented by taking topical gastric protectors or anti-secretory agents will be known.
Unité de Recherches Thérapeutiques, Hôpital Lariboisière, Paris.
J F
JF
Bergmann
L
L
Pichot
G
G
de Pouvourville
O
O
Chassany
C
C
Caulin
J M
JM
Segrestaa
D000863:Antacids / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D004378:Duodenal Diseases / Q000139:chemically induced / Q000191:economics / Q000517:prevention & control*; D005260:Female; D005602:France; D006306:Health Surveys; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D012307:Risk Factors; D013272:Stomach Diseases / Q000139:chemically induced / Q000191:economics / Q000517:prevention & control*; D011795:Surveys and Questionnaires
D000863:Antacids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D006635:Histamine H2 Antagonists
Prévention des lésions gastro-duodénales induites par les anti-inflammatoires non stéroïdiens. Analyse économique à partir d'un sondage réalisé chez 356 médecins.